Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Journal of Genetic Counseling
Erschienen in: Journal of Genetic Counseling 1/2011

01.02.2011 | Original Research

More Appreciation of Life or Regretting the Test? Experiences of Living as a Mutation Carrier of Huntington’s Disease

verfasst von: Anette Hagberg, The-Hung Bui, Elisabeth Winnberg

Erschienen in: Journal of Genetic Counseling | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

Little is known about how the knowledge of being a mutation carrier for Huntington’s disease (HD) influences lives, emotionally and socially. In this qualitative study 10 interviews were conducted to explore the long term (>5 years) experiences of being a mutation carrier. The results showed a broad variety of both positive and negative impact on the carriers’ lives. The most prominent positive changes reported were a greater appreciation of life and a tendency to bring the family closer together. On the other hand, some participants expressed decisional regrets and discussed the negative impact this knowledge had on their psychological well-being. The knowledge variously served as either a motivator or an obstacle in pursuing further education, career or investment in personal health. Deeper understanding of people’s reactions to the certainty of knowing they will become affected with HD is essential for the genetic counseling team in order to provide appropriate support.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Albom, M. (1997). Tuesdays with Morrie. New York: Random House.
Almqvist, E. W. (1996). Molecular genetic studies on Huntington disease. Dissertation thesis. Karolinska Institutet, Stockholm, Sweden.
Almqvist, E., Adam, S., Bloch, M., Fuller, A., Welch, P., Eisenberg, D., et al. (1997). Risk reversals in predictive testing for Huntington disease. American Journal of Human Genetics, 6, 945–952.CrossRef
Almqvist, E. W., Brinkman, R., Wiggins, S., & Hayden, M. R. (2003). Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington’s disease. Clinical Genetics, 64, 300–309.CrossRefPubMed
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: American Psychiatric Press.
Bloch, M., Fahy, M., Fox, S., & Hayden, M. R. (1989). Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes and psychosocial assessments of the first fifty-one test candidates. American Journal of Medical Genetics, 32, 217–224.CrossRefPubMed
Bloch, M., Adam, S., Wiggins, S., Huggins, M., & Hayden, M. R. (1992). Predictive testing for Huntington disease in Canada: the experience of those receiving an increased risk. American Journal of Medical Genetics, 42, 499–507.CrossRefPubMed
Codori, A.-M., & Brandt, J. (1994). Psychological costs and benefits of predictive testing for Huntington’s disease. American Journal of Medical Genetics, 54(3), 174–184.CrossRefPubMed
Decruyenaere, M., Evers-Kiebooms, G., Cloostermans, T., Boogaerts, A., Demyttenaere, K., Dom, R., et al. (2003). Psychological distress in the 5-year period after predictive testing for Huntington’s disease. European Journal of Human Genetics, 11, 30–38.CrossRefPubMed
DiCicco-Bloom, B., & Crabtree, F. B. (2006). The qualitative research interview. Medical Education, 40, 3014–3321.CrossRef
Duisterhof, M., Trijsburg, R. W., Niermeijer, M. F., Roos, R. A. C., & Tibben, A. (2005). Psychological studies in Huntington’s disease: making up the balance. Journal of Medical Genetics, 38, 852–861.CrossRef
Duncan, R. E., Gillam, L., Savulescu, J., Williamson, R., Rogers, J. G., & Delatycki, M. B. (2008). “You’re one of us now”: young people describe their experience of predictive genetic testing for Huntington disease (HD) and Familial Adenomatous Polyposis (FAP). American Journal of Medical Genetics Part C (Seminars in Medical Genetics), 148C, 47–55.CrossRef
Gargiulo, M., Lejeune, S., Tanguy, M.-L., Lahlou-Laforêt, K., Faudet, A., Cohen, D., et al. (2009). Long-term outcome of presymptomatic testing in Huntington disease. European Journal of Human Genetics, 17, 165–171.CrossRefPubMed
Gusella, J. F., Wexler, N. S., Conneally, P. M., Naylor, S. L., Anderson, M. A., Tanzi, R. E., et al. (1983). A polymorphic DNA marker genetically linked to Huntington’s disease. Nature, 306, 234–238.CrossRefPubMed
Hamann, H. A., Somers, T. J., Smith, A. W., Inslicht, S. S., & Baum, A. (2005). Posttraumatic stress associated with cancer history and BRCA 1/2 genetic testing. Psychosomatic Medicine, 67, 766–772.CrossRefPubMed
Hayden, M. R. (1981). Huntington’s chorea. Berlin: Springer Verlag.
Huggins, M., Bloch, M., Wiggins, S., Adam, S., Suchowersky, O., Trew, M., et al. (1992). Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. American Journal of Medical Genetics, 42, 508–515.CrossRefPubMed
Kondracki, N. L., Wellman, N. S., & Amundson, D. R. (2002). Content analysis: review of methods and their applications in nutrition education. Journal of Nutrition Education and Behavior, 34, 224–230.CrossRefPubMed
Kvale, S. (1996). Interviews: An introduction to qualitative research interviewing. Thousand Oaks: Sage.
Licklederer, C., Wolff, G., & Barth, J. (2008). Mental health and quality of life after genetic testing for Huntington disease: a long-term effect study in Germany. American Journal of Medical Genetics Part A, 146A, 2078–2085.CrossRefPubMed
Meissen, G. J., Mastromauro, C. A., Kiely, D. K., McNamara, D. S., & Myers, R. H. (1991). Understanding the decision to take the predictive test for Huntington disease. American Journal of Medical Genetics, 39, 404–410.CrossRefPubMed
O’Leary, V. (1998). Strength in the face of adversity: individual and social thriving. Journal of Social Issues, 54(2), 425–446.CrossRef
Parry, C., & Chesler, M. A. (2005). Thematic evidence of psychosocial thriving in childhood cancer survivors. Quality Health Research, 15(8), 1055–1073.CrossRef
Richards, F. (2004). Couples’ experiences of predictive testing and living with the risk or reality of Huntington disease: a qualitative study. American Journal of Medical Genetics, 126A, 170–182.CrossRefPubMed
Richards, F., & Williams, K. (2004). Impact on couple relationship of predictive testing for Huntington disease: a longitudinal study. American Journal of Medical Genetics, 126A, 161–169.CrossRefPubMed
Robins Wahlin, T.-B., Lundin, A., Bäckman, L., Almqvist, E., Haegermark, A., Winblad, B., et al. (1997). Reactions to predictive testing in Huntington disease: case reports of coping with a new genetic status. American Journal of Medical Genetics, 73, 356–365.CrossRef
Sobel, S. K., & Cowan, D. B. (2000). Impact of genetic testing for Huntington disease on the family system. American Journal of Medical Genetics, 90, 49–59.CrossRefPubMed
Tedeschi, R., Park, C., & Calhoun, L. (1998). Posttraumatic growth: Conceptual issues. In R. Tedeschi, C. Park, & L. Calhoun (Eds.), Posttraumatic growth. Positive changes in the aftermath of crisis (pp. 1–22). Mahwah: Erlbaum.
The Huntington’s Disease Collaborative Research Group. (1993). A novel gene containing trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosome. Cell, 72, 971–983.CrossRef
Tibben, A., Frets, P. G., van de Kamp, J. J. P., Niermeijer, M. F., Vegter-van der Vlis, M., Roos, R. A. C., et al. (1993a). Presymptomatic DNA-testing for Huntington disease: pretest attitudes and expectations of applicants and their partners in the Dutch program. American Journal of Medical Genetics (Neuropsychiatric Genetics), 48, 10–16.CrossRef
Tibben, A., Frets, P. G., van de Kamp, J. J. P., Niermeijer, M. F., Vegter-van der Vlis, M., Roos, R. A. C., et al. (1993b). On attitudes and appreciation 6 months after predictive DNA testing for Huntington disease in the Dutch program. American Journal of Medical Genetics, 48, 103–111.CrossRefPubMed
Tibben, A., Duivenvoorden, H. J., Niermeijer, M. F., Vegter-van der Vlis, M., Roos, R. A. C., Rooyman, H. G. M., et al. (1994). Psychological effects of presymptomatic DNA testing for Huntington’s disease in the Dutch program. Psychosomatic Medicine, 56(6), 526–532.PubMed
Tibben, A., Timman, R., Bannink, E. C., & Duivenvoorden, H. J. (1997). Three-year follow-up after presymptomatic testing for Huntington’s disease in tested individuals and partners. Health Psychology, 16(1), 20–35.CrossRefPubMed
Timman, R., Roos, R., Maat-Kievit, A., & Tibben, A. (2004). Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7-10 years after the test. Health Psychology, 23(2), 189–197.CrossRefPubMed
Wagner, A., van Kessel, I., Kriege, M. G., Tops, C. M. J., Wijnen, J. T., Vasen, H. F. A., et al. (2005). Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures. Familial Cancer, 4, 295–300.CrossRefPubMed
Wehbe, R. M., Spiridigliozzi, G. A., Heise, E. M., Dawson, D. V., & McConkie-Rosell, A. (2008). When to tell and test for genetic carrier status: perspectives of adolescents and young adults from fragile X families. American Journal of Medical Genetics, Part A, 149A, 1190–1199.CrossRef
Wiggins, S., Whyte, P., Huggins, M., Adam, S., Theilmann, J., Bloch, M., et al. (1992). The psychological consequences of predictive testing for Huntington’s disease. New England Journal of Medicine, 327, 1401–1405.CrossRefPubMed
Metadaten
Titel
More Appreciation of Life or Regretting the Test? Experiences of Living as a Mutation Carrier of Huntington’s Disease
verfasst von
Anette Hagberg
The-Hung Bui
Elisabeth Winnberg
Publikationsdatum
01.02.2011
Verlag
Springer US
Erschienen in
Journal of Genetic Counseling / Ausgabe 1/2011
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI
https://doi.org/10.1007/s10897-010-9329-6

Weitere Artikel der Ausgabe 1/2011

Journal of Genetic Counseling 1/2011 Zur Ausgabe

Original Research

“In Sickness and in Health”? Disclosures of Genetic Risks in Dating

Original Research

Boundary Issues and Multiple Relationships in Genetic Counseling Supervision: Supervisor, Non-supervisor, and Student Perspectives

Presidential Address

Presidential Address

Original Research

The Development of a Methodology for Examining the Process of Family Communication of Genetic Test Results

Original Research

Prevalence of Genetic Testing in CHARGE Syndrome

Professional Issues

Genetic Counseling Considerations in the Evaluation of Families for Lynch Syndrome—A Review

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Blutdrucksenkung könnte Uterusmyome verhindern

21.05.2024 Krebsvorsorge in der Gynäkologie Nachrichten

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise